|

Liberation day arrives, the fight back begins

Investors have been waiting for the announcement of Trump’s reciprocal tariffs, and today it will arrive. The President is set to announce the tariff arrangement at 2000 GMT, after US stock markets have closed. European stocks are lower today, however Japan’s Nikkei eked out a gain. US stock market futures are also pointing to a lower open later today. These pre-announcement moves are worth noting, firstly, they suggest that there is hope in markets that clarity about US tariffs will bring stability, hence the rise in the Nikkei. Secondly, US equities are more in the firing line than elsewhere.

Looking at Europe more closely. The Dax is the weakest performer in Europe so far on Wednesday. It is down more than 1%. This may be because Germany has the largest exposure to US tariffs since it has the highest value of trade to the US at EUR 161bn annually. Healthcare stocks are plummeting in the European session on Wednesday. Pharma exports are expected to get hit hard by Trump’s tariffs, and healthcare exports make up one of the biggest categories of exports to the US, along with cars and machinery.

Divergence to emerge within Europe

Can European stocks continue to outperform US stocks in the era of tariffs? In the short term it could depend on how much clarity we get today on the duration of tariffs and if there is room to negotiate. If President Trump does not deliver that clarity, then stock market could plummet. If Trump hints that some countries could negotiate lower rates of tariffs in the future based on the size of their current trade surplus with the US, then we may see some divergence in European shares. For example, the UK has a small trade deficit with the US, so the UK may be more likely to negotiate a lighter tariff package with the US in time, especially compared to Germany. Thus, UK pharma stocks could outperform their European counterparts in the short and medium term.

The chart below shows UK pharma giants including Smith and Nephew, GSK and Astra Zeneca, along with European healthcare firms including Sanofi and Bayer. This chart has been normalized to show how they move together over the past year. As you can see, there has been no notable regional dispersion in performance in recent weeks. The weakest pharma companies include GSK and Bayer, although all of the companies in this chart have weakened in March. However, if it starts to look likely that the UK can negotiate a lower tariff rate with the US compared to the EU, then GSK, the UK pharma giant, could be ripe to outperform.

European and UK pharma giants, normalized to show how they move together over the past year

Chart

Source: XTB

The fight back begins

Financial markets are also signaling that tariffs may not be as disruptive for global trade as some think. For example, there could be an effective fight back against American protectionism. If all countries that trade with the US face tariffs, some will have tariffs that are higher than others. This means that some countries will have a trade advantage with the US. One of these could be Brazil.

The Ibovespa, the Brazilian stock market, rose by 6.8% last month, compared with a 5% decline for the S&P 500. Likewise, the Brazilian real is higher by 9% YTD vs. the USD, which is another sign that Brazil could be a big winner from President Trump’s tariff policy. For example, the Brazil could have lower tariff rates compared to China. Since it manufacturers some of the same goods, e.g. shoes, if tariff rates are lower in Brazil compared to China, it may protect Brazilian market share in the US. Added to this, Brazil is a commodity heavy economy. If China and the rest of the world turn away from US exports of agricultural products etc., then Brazil could fill the gap.

The outperformance of Brazilian asset prices is a sign of 1, optimism over Brazil’s trade future and 2, a positive sign that just because America is turning inwards, there will still be some winners in the trade war and that should be reflected in the stock market.

Is this a peak for the Gold price?

US durable goods orders are scheduled for release later today; however, the focus is on the tariff update, and we expect financial markets to continue to drift lower until then. Gold has made a fresh intraday record high on Wednesday, which is another sign that gold is the ultimate tariff trade. The gold price will face a big test ahead: if US stock markets start to rally after the tariff announcement is out of the way, can the gold price continue to rally? We think that a lot of the rally in the gold price is linked to US economic policy uncertainty, once this starts to recede, the gold price could follow. 

Author

Kathleen Brooks

Kathleen has nearly 15 years’ experience working with some of the leading retail trading and investment companies in the City of London.

More from Kathleen Brooks
Share:

Markets move fast. We move first.

Orange Juice Newsletter brings you expert driven insights - not headlines. Every day on your inbox.

By subscribing you agree to our Terms and conditions.

Editor's Picks

EUR/USD moves sideways below 1.1800 on Christmas Eve

EUR/USD struggles to find direction and trades in a narrow channel below 1.1800 after posting gains for two consecutive days. Bond and stock markets in the US will open at the usual time and close early on Christmas Eve, allowing the trading action to remain subdued. 

GBP/USD keeps range around 1.3500 amid quiet markets

GBP/USD keeps its range trade intact at around 1.3500 on Wednesday. The Pound Sterling holds the upper hand over the US Dollar amid pre-Christmas light trading as traders move to the sidelines heading into the holiday season. 

Gold retreats from record highs, trades below $4,500

Gold retreats after setting a new record-high above $4,520 earlier in the day and trades in a tight range below $4,500 as trading volumes thin out ahead of the Christmas break. The US Dollar selling bias remains unabated on the back of dovish Fed expectations, which continues to act as a tailwind for the bullion amid persistent geopolitical risks.

Bitcoin slips below $87,000 as ETF outflows intensify, whale participation declines

Bitcoin price continues to trade around $86,770 on Wednesday, after failing to break above the $90,000 resistance. US-listed spot ETFs record an outflow of $188.64 million on Tuesday, marking the fourth consecutive day of withdrawals.

Economic outlook 2026-2027 in advanced countries: Solidity test

After a year marked by global economic resilience and ending on a note of optimism, 2026 looks promising and could be a year of solid economic performance. In our baseline scenario, we expect most of the supportive factors at work in 2025 to continue to play a role in 2026.

Avalanche struggles near $12 as Grayscale files updated form for ETF

Avalanche trades close to $12 by press time on Wednesday, extending the nearly 2% drop from the previous day. Grayscale filed an updated form to convert its Avalanche-focused Trust into an ETF with the US Securities and Exchange Commission.